Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15307442 | 0.79 | TSHR (0.40) | TSHRPPARDTDP1TP53 | |
| SCHEMBL10542745 | 0.76 | TSHR (0.62) | TSHRPPARDTDP1TP53MEN1 | |
| SCHEMBL3313657 | 0.68 | PPARD (0.70) | TSHRPPARDTDP1TP53MEN1 | |
| SCHEMBL5961215 | 0.68 | TSHR (1.00) | TSHRPPARDTDP1TP53MEN1 | |
| SCHEMBL26483 | 0.68 | TSHR (1.00) | TSHRPPARDTDP1TP53MEN1 | |
| SCHEMBL282472 | 0.68 | TSHR (0.67) | TSHRPPARDTDP1TP53MEN1 | |
| SCHEMBL4958485 | 0.67 | TSHR (0.65) | TSHRPPARDTDP1TP53MEN1 | |
| SCHEMBL11745101 | 0.66 | TSHR (0.94) | TSHRPPARDTDP1TP53MEN1 | |
| SCHEMBL13656095 | 0.66 | — | — | |
| SCHEMBL9654507 | 0.66 | TSHR (0.63) | TSHRPPARDTDP1TP53MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025073792-A1 | WRN INHIBITORY COMPOUNDS | FORX THERAPEUTICS AG (CH) | 2025-04-10 | — | — | WO | disclosed |
| EP-2288615-B1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | GENESIS TECH LTD (BB) | 2017-06-21 | — | — | EP | disclosed |
| CN-104619683-B | Process for the preparation of optionally substituted phenyl and pyridyl pyrrolidines | 拜耳农作物科学股份公司 | 2017-05-10 | — | — | CN | disclosed |
| US-9447036-B2 | Process for the preparation of optionally substituted phenyl and pyridyl pyrrolidines | BAYER CROPSCIENCE AG (DE) | 2016-09-20 | — | — | US | disclosed |
| US-9447036-B2 | Process for the preparation of optionally substituted phenyl and pyridyl pyrrolidines | BAYER CROPSCIENCE AG (DE) | 2016-09-20 | — | — | US | disclosed |
| US-20150246880-A1 | PROCESS FOR THE PREPARATION OF OPTIONALLY SUBSTITUTED PHENYL AND PYRIDYL PYRROLIDINES | BAYER CROPSCIENCE AG (DE) | 2015-09-03 | — | — | US | disclosed |
| US-20150246880-A1 | PROCESS FOR THE PREPARATION OF OPTIONALLY SUBSTITUTED PHENYL AND PYRIDYL PYRROLIDINES | BAYER CROPSCIENCE AG (DE) | 2015-09-03 | — | — | US | disclosed |
| CN-104619683-A | Process for the preparation of optionally substituted phenyl and pyridyl pyrrolidines | BAYER CROPSCIENCE AG | 2015-05-13 | — | — | CN | disclosed |
| WO-2012034232-A1 | TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS | NEUROQUEST INC. (CA) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246880-A1 | PROCESS FOR THE PREPARATION OF OPTIONALLY SUBSTITUTED PHENYL AND PYRIDYL PYRROLIDINES | TYMP, DHPS, PNPO | TSHR 1842/4885PPARD 563/4885TDP1 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.